Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the ...

No Shareholder Action is Required at this TimeBOSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: ...

Atea Pharmaceuticals has already laid off a quarter of its workforce so far this year as the biotech prepares to launch a phase 3 trial of its hepatitis C cocktail. The treatment—a combination ...

BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral ...

The Atea Board of Directors and management team have recently taken several decisive actions to enhance shareholder value, including: Launching a comprehensive review of strategic opportunities - In ...

Atea Pharmaceuticals (AVIR) confirmed receipt of a notice from Bradley Radoff that he intends to nominate three director candidates to stand for election to the Atea board of directors at the ...

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company) a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral ...

BOSTON - Atea Pharmaceuticals, Inc. (NASDAQ:AVIR), a clinical-stage biopharmaceutical company with a market capitalization of $271.5 million, has announced a series of measures aimed at enhancing ...